Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of the Safety, Pharmacokinetics, and Duration of Effect of Intravitreally Administered AIV007 Gel Suspension in Subjects With Neovascular Age-Related Macular Degeneration

NCT04422899 is registered in ClinicalTrials.gov with AiViva BioPharma, Inc. as lead sponsor.

NCT NCT04422899
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04422899 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of the Safety, Pharmacokinetics, and Duration of Effect of Intravitreally Administered AIV007 Gel Suspension in Subjects With Neovascular Age-Related Macular Degeneration
Lead sponsor
AiViva BioPharma, Inc.
Phase
Phase 1
Overall status
Completed
Start date
August 28, 2020
Completion date
February 28, 2022
Enrollment
3 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age-related macular degeneration